Introducing ROZIA-25 (Empagliflozin Tablets)
C & D Biosciences, a Division of R.P.P.L., is proud to announce the launch of ROZIA-25 (Empagliflozin Tablets 25 mg), the latest addition to its expanding portfolio of high-quality pharmaceutical products. Developed for the management of Type 2 Diabetes Mellitus (T2DM), ROZIA-25 reflects our commitment to innovation, quality, and better patient care.
~Supports modern Type 2 Diabetes management with confidence
~Quality-assured Empagliflozin 25 mg formulation
~Manufactured under stringent international quality standards
~Backed by C & D Biosciences’ commitment to pharmaceutical excellence
Decoding ROZIA-25: The Science Behind the New Launch
ROZIA-25 contains Empagliflozin 25 mg, packed in 10*10 tablets, an SGLT2 inhibitor indicated for adults with Type 2 Diabetes Mellitus according to the approved prescribing information. It works by reducing glucose reabsorption in the kidneys, enabling excess glucose to be eliminated through urine and thereby improving glycemic control.
The launch of ROZIA-25 (Empagliflozin Tablets) demonstrates C & D Biosciences’ continued commitment to providing high-quality pharmaceutical solutions that support evidence-based clinical practice. Every tablet is manufactured with a focus on quality, consistency, and reliability, helping healthcare professionals deliver trusted diabetes care.
Why the Choice of ROZIA-25 ?
The introduction of ROZIA-25 (Empagliflozin Tablets) marks another significant milestone for C & D Biosciences in strengthening its diabetes care portfolio. As the burden of diabetes continues to increase, dependable pharmaceutical products play an important role in supporting healthcare professionals and improving patient care.
Key Features of ROZIA-25
~Empagliflozin 25 mg film-coated tablets
~High-quality formulation
~Manufactured under stringent quality standards
~Developed for adults with Type 2 Diabetes Mellitus as per approved indications
~Trusted product from C & D Biosciences
~Commitment to quality, innovation, and patient-centric care
Our Commitment to Quality
At C & D Biosciences, quality is more than a standard—it is our commitment. Every product is developed with an emphasis on safety, consistency, regulatory compliance, and manufacturing excellence. The launch of ROZIA-25 (Empagliflozin Tablets) reflects our mission to provide dependable pharmaceutical solutions.
Through continuous innovation and uncompromising quality, we strive to contribute to better healthcare outcomes while earning the trust of physicians, pharmacists, and patients.
C & D Biosciences – Advancing Cardiac & Diabetic Care
C & D Biosciences, a Division of R.P.P.L., is committed to delivering high-quality pharmaceutical products across Cardiac & Diabetic Care. Our growing portfolio is designed to support healthcare professionals with reliable and innovative treatment solutions that meet evolving medical needs.
The launch of ROZIA-25 (Empagliflozin Tablets 25 mg) further strengthens our diabetes care portfolio and reflects our dedication to developing trusted pharmaceutical products backed by quality manufacturing and scientific excellence.
As we continue to expand our range of Cardiac & Diabetic Care products, our focus remains on building lasting partnerships with healthcare professionals, distributors, stockists, and business associates while contributing to better patient outcomes through quality medicines.
C & D Biosciences – A Division of R.P.P.L. continues to move forward with a vision of delivering innovative, reliable, and quality-driven pharmaceutical solutions for a healthier tomorrow.
Conclusion
The launch of ROZIA-25 (Empagliflozin Tablets 25 mg) represents another important milestone in the journey of C & D Biosciences, a Division of R.P.P.L. By strengthening our diabetes care portfolio, we reaffirm our commitment to quality, innovation, and supporting healthcare professionals with dependable pharmaceutical solutions.
With ROZIA-25, C & D Biosciences continues its mission of improving healthcare through responsible pharmaceutical innovation, trusted quality, and excellence in patient care.
Disclaimer: ROZIA-25 should be prescribed and used only in accordance with the approved prescribing information. Healthcare professionals should evaluate individual patient requirements and follow applicable local regulatory guidelines.
Contact Us Today
To learn more about ROZIA-25 (Empagliflozin Tablets) or explore our comprehensive range of Cardiac & Diabetic Care products, connect with C & D Biosciences, a Division of R.P.P.L.
Phone: +91 9592087880
Email: rouzelpharmapl@gmail.com
Website: www.rouzelpharma.in
